Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study

BACKGROUND: Secondary hyperparathyroidism (SHPT) is frequent in haemodialysis (HD) patients. Oral cinacalcet-hydrochloride (HCl) decreases parathyroid hormone (PTH); however, real-life PTH data, according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, are still lacking. Our goal is...

Descripción completa

Detalles Bibliográficos
Autores principales: Rottembourg, Jacques, Ureña-Torres, Pablo, Toledano, Daniel, Gueutin, Victor, Hamani, Abdelaziz, Coldefy, Olivier, Hebibi, Hedia, Guincestre, Thomas, Emery, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
CKD-Mbd
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885690/
https://www.ncbi.nlm.nih.gov/pubmed/31807302
http://dx.doi.org/10.1093/ckj/sfz021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885690/
https://www.ncbi.nlm.nih.gov/pubmed/31807302
http://dx.doi.org/10.1093/ckj/sfz021

Ejemplares similares